A multivariate generalized linear model of the effect of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in end-stage renal disease

1 Mohammed RB, Mohammed MM. Potential role of niacin as adjuvant to sevelamer on serum levels of inorganic phosphorus, calcium and calcium-phosphorus product in hemodialysis patients with hyperphosphatemia. Res J Pharm Tech. 2022;15(5):2158-62. Search in Google Scholar

2 Braun MM, Khayat M. Kidney disease: End-stage renal disease. FP Essent. 2021;509:26-32. Search in Google Scholar

3 Rocha AD, Garcia S, Santos AB, Eduardo JCC, Mesquita CT, Lugon JR, et al. No race-ethnicity adjustment in CKD-EPI equations is required for estimating glomerular filtration rate in the Brazilian population. Int J Nephrol. 2020;2020:2141038. Search in Google Scholar

4 Oweis AO, Al-Qarqaz F, Bodoor K, Heis L, Alfaqih MA, Almomani R, et al. Elevated interleukin 31 serum levels in hemodialysis patients are associated with uremic pruritus. Cytokine. 2021;138:155369. Search in Google Scholar

5 Dizdar OS, Yıldız A, Gul CB, Gunal AI, Ersoy A, Gundogan K. The effect of hemodialysis, peritoneal dialysis and renal transplantation on nutritional status and serum micronutrient levels in patients with end-stage renal disease; Multicenter, 6-month period, longitudinal study. J Trace Elem Med Biol. 2020;60:126498. Search in Google Scholar

6 Song YR, Kim JK, Lee HS, Kim SG, Choi EK. Serum levels of protein carbonyl, a marker of oxidative stress, are associated with overhydration, sarcopenia and mortality in hemodialysis patients. BMC Nephrol. 2020;21(1):281. Search in Google Scholar

7 Ravarotto V, Simioni F, Pagnin E, Davis PA, Calò LAJLs. Oxidative stress – chronic kidney disease – cardiovascular disease: A vicious circle. Life Sci. 2018;210:125-31. Search in Google Scholar

8 Zemaitis MR, Foris LA, Katta S, Bashir K. Uremia. Treasure Island (FL): StatPearls Publishing; 2024. Search in Google Scholar

9 Naber T, Purohit S. Chronic Kidney Disease: Role of Diet for a Reduction in the severity of the disease. Nutrients. 2021;13(9):3277. Search in Google Scholar

10 Block GA, Ix JH, Ketteler M, Martin KJ, Thadhani RI, Tonelli M, et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis. 2013;62(3):457-73. Search in Google Scholar

11 Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008;3(5):1535-41. Search in Google Scholar

12 Wani N, Pasha T. Laboratory tests of renal function. Anaesth Intens Care Med. 2021;22(7):393-7. Search in Google Scholar

13 Maraj M, Hetwer P, Dumnicka P, Ceranowicz P, Mazur-Laskowska M, Zabek-Adamska A, et al. Acute phase proteins and vitamin D seasonal variation in end-stage renal disease patients. J Clin Med. 2020;9(3):807. Search in Google Scholar

14 Bassiouni W, Ali MA, Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS J. 2021; 288(24):7162-82. Search in Google Scholar

15 Bjerkeli V, Halvorsen B, Damås J, Nordøy I, Yndestad A, Aukrust P, et al. Expression of matrix metalloproteinases in patients with Wegener’s granulomatosis. Ann Rheum Dis. 2004;63(12):1659-63. Search in Google Scholar

16 Zakiyanov O, Kalousová M, Zima T, Tesař V. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease. Adv Clin Chem. 2021;105:141-212. Search in Google Scholar

17 Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int. 1997;52(1):111-9. Search in Google Scholar

18 Martins VL, Caley M, O’Toole EA. Matrix metalloproteinases and epidermal wound repair. Cell Tissue Res. 2013;351(2):255-68. Search in Google Scholar

19 Gomez D, Alonso D, Yoshiji H, Thorgeirsson U. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74(2):111-22. Search in Google Scholar

20 Martin DC, Sanchez-Sweatman OH, Ho A, Inderdeo DS, Tsao M-S, Khokha R. Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab Invest. 1999;79(2):225-34. Search in Google Scholar

21 Kanauchi M, Nishioka H, Nakashima Y, Hashimoto T, Dohi K. Role of tissue inhibitors of metalloproteinase in diabetic nephropathy. Nihon Jinzo Gakkai Shi. 1996;38(3):124-8. Search in Google Scholar

22 Carome M, Striker L, Peten E, Moore J, Yang C, Stetler-Stevenson W, et al. Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA. Am J Physiol. 1993;264(6):F923-F9. Search in Google Scholar

23 Kökény G, Németh Á, Kopp JB, Chen W, Oler AJ, Manzéger A, et al. Susceptibility to kidney fibrosis in mice is associated with early growth response-2 protein and tissue inhibitor of metalloproteinase-1 expression. Kidney Int. 2022;102(2):337-54. Search in Google Scholar

24 Mora-Gutiérrez JM, Rodríguez JA, Fernández-Seara MA, Orbe J, Escalada FJ, Soler MJ, et al. MMP-10 is increased in early stage diabetic kidney disease and can be reduced by renin-angiotensin system blockade. Sci Rep. 2020;10(1):1-12. Search in Google Scholar

25 25. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766-72. Search in Google Scholar

26 Mateu-de Antonio JJMP, Practice. New predictive equations for serum ionized calcium in hospitalized patients. Med Princ Pract. 2016;25(3):219-26. Search in Google Scholar

27 Koch SM, Warters RD, Mehlhorn U. The simultaneous measurement of ionized and total calcium and ionized and total magnesium in intensive care unit patients. J Crit Care. 2002;17(3):203-5. Search in Google Scholar

28 Velasquez-Mao AJ, Velasquez MA, Hui Z, Armas-Ayon D, Wang J, Vandsburger MH. Hemodialysis exacerbates proteolytic imbalance and pro-fibrotic platelet dysfunction. Sci Rep. 2021;11(1):11764. Search in Google Scholar

29 Ishizaki M, Matsunaga T, Adachi K, Miyashita E. Serum matrix metalloproteinase-3 in hemodialysis patients with dialysis-related amyloidosis. Hemodialysis Int. 2004;8(3):219-25. Search in Google Scholar

30 Musiał K, Zwolińska D. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinases as novel stress markers in children and young adults on chronic dialysis. Cell Stress Chaperones. 2011;16(2):163-71. Search in Google Scholar

31 Preston GA, Barrett CV, Alcorta DA, Hogan SL, Dinwiddie L, Jennette JC, et al. Serum Matrix Metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 Levels. Nephron. 2002;92(4):817-23. Search in Google Scholar

32 Pawlak K, Pawlak D, Mysliwiec M. Circulating β-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients–Role of oxidative stress. Cytokine. 2005;31(1):18-24. Search in Google Scholar

33 Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol. 2012;302(11):F1351-61. Search in Google Scholar

34 Fouque D, Roth H, Darne B, Bouchet JL, Daugas E, Drueke TB, et al. Achievement of 2009 and 2017 Kidney Disease: Improving Global Outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients. Clin Kidney J. 2018;11(5):710-9. Search in Google Scholar

35 Rastogi A, Bhatt N, Rossetti S, Beto J. Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm. J Ren Nutr. 2021;31(1):21-34. Search in Google Scholar

36 Garabed E, Norbert L, Bertram L. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. Search in Google Scholar

37 Crespo-Salgado J, Vehaskari VM, Stewart T, Ferris M, Zhang Q, Wang G, et al. Intestinal microbiota in pediatric patients with end stage renal disease: a midwest pediatric nephrology consortium study. Microbiome. 2016;4(1):50. Search in Google Scholar

38 Laville SM, Couturier A, Lambert O, Metzger M, Mansencal N, Jacquelinet C, et al. Urea levels and cardiovascular disease in patients with chronic kidney disease. Nephrol Dial Transplant. 2022;38(1):184-92. Search in Google Scholar

39 Russo E, Viazzi F, Pontremoli R, Barbagallo CM, Bombelli M, Casiglia E, et al. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. J Nephrol. 2021:1-11. Search in Google Scholar

40 Cirillo M, Laurenzi M, Mancini M, Zanchetti A, Lombardi C, De Santo NG. Low glomerular filtration in the population: prevalence, associated disorders, and awareness. Kidney Int. 2006; 70(4):800-6. Search in Google Scholar

41 Beto J, Bhatt N, Gerbeling T, Patel C, Drayer D. Overview of the 2017 KDIGO CKD-MBD update: practice implications for adult hemodialysis patients. J Ren Nutr. 2019;29(1):2-15. Search in Google Scholar

42 Goodman WG, editor The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Seminars in dialysis; 2004: Wiley Online Library. Search in Google Scholar

43 Liu H, Wang R. Associations between the serum magnesium and all-cause or cardiovascular mortality in chronic kidney disease and end-stage renal disease patients: A meta-analysis. Medicine. 2021;100(45). Search in Google Scholar

44 Palumbo VD, Palumbo VD, Damiano G, Messina M, Fazzotta S, Lo Monte G, et al. Tertiary hyperparathyroidism: a review. Clin Ter. 2021;172(3):241-6. Search in Google Scholar

45 Rymarz A, Mosakowska M, Niemczyk S. The significance of metalloproteinase 3 (MMP-3), chemokine CXC ligand 13 (CXCL-13) and complement component C5a in different stages of ANCA associated vasculitis. Sci Rep. 2021;11(1):5132. Search in Google Scholar

46 Ozkan H, Okuturlar Y, Kocoglu H, Hursitoglu M, Gedikbasi A, Utku IK, et al. Serum levels and urinary excretion of tenascin-C and TIMP-1 in acute kidney injury. Clin Lab. 2019;65(10). Search in Google Scholar

47 Lieb W, Song RJ, Xanthakis V, Vasan RS. Association of circulating tissue inhibitor of metalloproteinases-1 and procollagen type III aminoterminal peptide levels with incident heart failure and chronic kidney disease. J Am Heart Assoc. 2019;8(7):e011426. Search in Google Scholar

48 Caimi G, Hopps E, Montana M, Urso C, Carollo C, Canino B, et al. The function of matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1) in several clinical conditions: Results and analysis of our survey. J Clin Hematol Microcirc. 2021;78(4):401-16. Search in Google Scholar

49 Won AJ, Kim S, Kim YG, Kim KB, Choi WS, Kacew S, et al. Discovery of urinary metabolomic biomarkers for early detection of acute kidney injury. Mol Biosyst. 2016;12(1):133-44. Search in Google Scholar

50 Atamaniuk J, Kopecky C, Skoupy S, Saemann MD, Weichhart T. Apoptotic cell-free DNA promotes inflammation in haemodialysis patients. Nephrol Dial Transplant. 2012;27(3):902-5. Search in Google Scholar